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Echocardiography in Liver Transplant Candidates
Anubhav Garg, MD, William F. Armstrong, MD
Ann Arbor, Michigan
Involvement of the cardiovascular system inpatientswith end-stage liver disease (ESLD) iswell recognized
and may be seen in several scenarios in adult liver transplantation (LT) candidates. The hemodynamic
effects of ESLD may result in apparent heart disease, or in some instances may mask cardiac disease.
Alternatively, cardiac disease can occasionally be the underlying etiology of ESLD. LT imposes significant
hemodynamic stresses, with cardiovascular complications accounting for considerable perioperative
mortality and morbidity. Pre-operative assessment of the cardiac status of LT candidates is thus critically
important for risk stratification andmanagement. Cardiac imaging plays an integral role in the assessment
of LT candidates. In this review, we discuss the role of cardiac imaging, including transthoracic echocardi-
ography with Doppler and contrast enhancement, noninvasive functional assessment for routine pre-
operative assessment of coronary artery disease, and transesophageal echocardiography in select cases to
aid in intra-operative fluidmanagement andmonitoring in LT candidates. (J AmColl Cardiol Img 2013;6:
105–19) © 2013 by the American College of Cardiology Foundationular
o renvolvement of the cardiovascular system in
end-stage liver disease (ESLD) is well recog-
nized and results in several distinct clinical
scenarios. The hemodynamic effects of ESLD
may result in apparent heart disease or in some
instances may mask cardiac disease. ESLD
results in a constellation of secondary cardio-
vascular effects referred to as “cirrhotic car-
diomyopathy”—a form of cardiac dysfunction
characterized by cardiac structural changes, di-
astolic dysfunction, and baseline supernormal
cardiac output with impaired contractile re-
serve in response to stress (1). Liver trans-
plantation (LT) imposes significant hemody-
namic stresses with cardiovascular events
reported in up to 70% of LT recipients (2).
Less common cardiovascular abnormalities in
LT candidates include pulmonary heart dis-
ease, pericardial effusions, and intracardiac
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Cardiac imaging plays an integral role in the
assessment of LT candidates. While computed
tomography (CT), cardiac magnetic resonance
(CMR), and angiography have all been used
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ESLD, echocardiography remains the most
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106Cardiovascular Hemodynamics and Disease in ESLD
Hemodynamics of ESLD cirrhotic cardiomyopathy. Pa-
tients with ESLD have decreased sinusoidal, but
increased peripheral, nitric oxide production, lead-
ing to portal hypertension and splanchnic and
peripheral vasodilatation (3,4). ESLD is also char-
acterized by an expansion and redistribution of
circulating blood volume, resulting in relative
splanchnic hypervolemia and effective central hypo-
volemia (3,5). The combination of decreased sys-
temic vascular resistance with central hypovolemia
leads to a hyperdynamic circulatory state that is
unique to patients with ESLD (4–9). This hemo-
dynamic state results in increased pulmo-
nary and systemic flows at baseline with
high normal or elevated right ventricular
(RV), pulmonary artery, and left-atrial
(LA) or pulmonary capillary wedge pres-
sures (Table 1) (4,5). This hemodynamic
profile is noted in patients with ESLD not
complicated by pulmonary vascular disease
or primary cardiac disease (Figs. 1, 2, and 3;
Online Videos 1 and 2).
In the LT candidate, pre-operative car-
diac compromise and overt heart failure is
rarely present as left-ventricular (LV) dys-
function is masked by the peripheral vaso-
dilatation associated with ESLD (7).
However, an impaired cardiac ventricular
response to physiological or pharmacolog-
ical stress may be present despite the
increase in baseline cardiac output (8,9).
This impaired hemodynamic response to
stress in the absence of primary cardiac
disease is the hallmark of cirrhotic cardio-
myopathy (8,9). This latent LV systolic
dysfunction results from a combination
of the following: 1) decreased beta-
adrenergic receptor density and function; and 2)
negative inotropic effect of endocannabinoids and
nitric oxide, both of which are upregulated in the
setting of cirrhosis (1,3). The prevalence of cirrhotic
cardiomyopathy is unknown as it is often difficult to
establish the diagnosis due to the normal or hyper-
dynamic cardiac function at rest and the presence of
concurrent primary cardiac disease (3,10).
In addition to masked systolic dysfunction, cir-
rhotic cardiomyopathy may be accompanied by
diastolic dysfunction and structural and electrical
cardiac abnormalities (8,9,11). The increased myo-
cardial stiffness found in patients with cirrhosis is
ion
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f
se
ase
arthought to reflect a combination of LV hypertrophy(LVH), myocardial fibrosis, and subendothelial
edema secondary to ESLD (4,5,9). Several studies
have documented impaired ventricular relaxation in
cirrhotic patients noted as a nonsignificant increase
in the E-wave velocity, significantly increased
A-wave velocity, increased deceleration time, and
decreased E/A ratio when compared to controls
(6,11,12) (Fig. 4). Patients with ascites have more
pronounced diastolic dysfunction than patients
without ascites (6,13).
A recent autopsy study of 133 patients with
cirrhosis and no known history of heart disease
revealed significant cardiac abnormalities in 43%,
with cardiomegaly and LVH the most common
Table 1. Baseline Hemodynamic Changes in Patients
With ESLD
Hemodynamic Parameter Changes
Systemic circulation Plasma volume 1, total blood
volume 1, noncentral blood
volume 1, central blood
volume 2 ↔, arterial blood
pressure ↔ 2, systemic
vascular resistance 2, heart
rate 1, cardiac output 1
Cardiac hemodynamics LA volume 1, LV volume 1 ↔,
right atrial volume ↔ 1 2,
RV volume ↔ 1 2, RA
pressure ↔ 1, RV end-
diastolic pressure ↔,
pulmonary capillary wedge
pressure ↔, LV end-diastolic
pressure 1 ↔
Pulmonary circulation Pulmonary blood ﬂow 1,
pulmonary artery pressure ↔
1, pulmonary vascular
resistance ↔ 1 2
↔  No change; 1  increase; 2  decrease; ESLD  end-stage liver
disease; LA  left-atrial; LV  left-ventricular; RA  right-atrial; RV  right
ventricular.
Figure 1. Apical 4-Chamber View Recorded in a Patient
With ESLD
Note the left atrial (LA) dilation (LA area, 25.5 cm2) and hyperdy-
namic left ventricular (LV) function (LV ejection fraction, 72%).
(See Online Video 1). ESLD  end-stage liver disease.A B B R E V I A T I O N S
A N D A C R O N YM S
AASLD American Associat
for the Study of Liver Diseas
ACCF American College o
Cardiology Foundation
AHA American Heart
Association
CAD coronary artery disea
DSE dobutamine stress
echocardiography
ESLD end-stage liver dise
HPS hepatopulmonary
syndrome
LT liver transplantation
LV left ventricle/ventricul
LVH left-ventricular
hypertrophy
LVOTO left-ventricular
outflow tract obstruction
PPH portopulmonary
hypertension
TTE transthoracic
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107findings (14). Numerous studies have evaluated
cardiac chamber sizes in patients with ESLD al-
though with conflicting results. Using echocardiog-
raphy, Pozzi et al. (6) and Abd-El-Aziz et al. (11)
found that LA size was significantly larger but LV
size was similar in cirrhotic patients as compared to
controls. In contrast, Finucci et al. (12) found
significantly increased left atrial volumes, LV end
diastolic volumes, and stroke volumes in cirrhotic
patients compared to controls. In contrast, right-
sided cardiac chamber sizes can be reduced, normal
in size, or enlarged, likely depending on the pres-
ence of accompanying pulmonary vascular disease
(5). Mild LVH is a common finding in cirrhotic
cardiomyopathy (6,11,12). Although the mecha-
nism of LVH is not completely understood, it is
presumed to result from a combination of me-
chanical overload in the setting of chronically
increased cardiac output and activation of the
neuroendocrine system, especially in the setting
of ascites (6,13).
Coronary Artery Disease
The prevalence of CAD in ESLD previously was
thought to be lower than in the general population
related to abnormal synthetic liver function result-
ing in lower cholesterol, lower blood pressure, and
higher levels of circulating estrogens (15,16). More
recent studies have demonstrated that LT candi-
dates have a significantly greater prevalence of
CAD than previously thought (15). In studies
utilizing cardiac catheterization for all enrolled
patients, the prevalence of CAD has ranged from
18% to 27% (Table 2) (17–19). Risk factors for the
resence of CAD included older age, male gen-
er, hypertension or diabetes, and non–alcohol-
elated etiology of cirrhosis (17–19). Studies have
lso revealed a significant burden of unrecog-
ized, asymptomatic CAD (1,15). Carey et al.
17) reported that 13.3% of LT candidates with
oderate or severe coronary stenosis were asymp-
omatic, presumably due to the masking effect of
oor functional status.
ESLD patients with CAD have worse outcomes
han patients without CAD (20). In patients with
nown CAD who underwent LT, Plotkin et al.
20) reported a 30-day 25% mortality rate, an
verall mortality rate of 50%, and morbidity rate of
1%. Cardiovascular disease continues to contribute
o late mortality after transplantation due to the
econdary development of hypertension, hyperlip-
demia, diabetes, and obesity from chronic immu- wnosuppression (15,16). Cardiovascular disease is the
second most common cause of death (21%) 1 year
after transplantation (21) and the third most com-
mon cause (21%) 3 years after transplantation (22).
With greater emphasis on improved assessment and
revascularization of CAD pre-operatively, Diedrich
et al. (23) recently showed an improvement in the
overall mortality rate to 26% and morbidity rate
to 38%.
Noninvasive assessment of the liver transplant candi-
date. Currently, the American Association for the
tudy of Liver Diseases (AASLD) recommends
outine TTE for all LT candidates for the assess-
ent of chamber sizes, hypertrophy, systolic and
iastolic function, valvular function, and LV out-
ow tract obstruction (LVOTO) (24). In patients
Figure 2. TVIs Recorded in a Patient With ESLD
Note the upper normal to elevated time-velocity integrals (TVIs) of
outﬂow track of 27 cm (top panel) and LV outﬂow track of 39 cm
ative of the high-ﬂow state. Abbreviations as in Figure 1.the right ventricular
(bottom panel) indic-ith ESLD, TTE should reveal normal or super-
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108normal LV systolic function at rest; the finding of
“normal” or reduced ejection fraction should raise
suspicion of an underlying cardiomyopathy or CAD
and merits further evaluation. Other imaging mo-
dalities have been utilized, including single photon
emission computed tomography (SPECT), com-
puted tomography angiography (CTA), and CMR,
although the bulk of the available data are with
echocardiography.
ESLD, especially if complicated by hepatomeg-
aly and ascites, may pose distinct problems with
imaging. These issues may include technical diffi-
culty with acquisition of high-quality images and
issues relating to accurate diagnoses, which are
specific to the pathophysiology of ESLD. In gen-
eral, with CTA or CMR, the only technical issues
include control of respiratory rate and/or breath
holding in patients with ascites who may have
Elevation of Right Ventricular Systolic Pressure in a Patient With
se
ﬂow track view revealing high-velocity inﬂow from the inferior
ith a high ﬂow state. (B) Tricuspid regurgitation jet revealing a
m/s corresponding to a right ventricular to right-atrial pressure
consistent with mild elevation of pulmonary artery pressures.respiratory compromise while supine. Other thanthis, the relative and absolute contraindications are
the same in the ESLD patient as in the general
population. When utilizing SPECT for assessment
of CAD, diaphragmatic attenuation may be noted
related to elevation of the diaphragm and/or hepa-
tomegaly shadowing the inferior port of the heart
and thus mimicking an inferior perfusion defect.
Echocardiographic imaging of the patient with
ESLD may be complicated by ascites, which limits
the ability to image from the subcostal position and
may alter the orientation of the heart within the
thorax such that off-axis views and unconventional
imaging windows are necessary. In general, acqui-
sition of clinical quality images is feasible in the
majority of patients. The echocardiographer must
recognize the anticipated physiological changes in
ESLD, including high volume flow and mild de-
grees of chamber enlargement. On occasion, ascites
may distort the contour of the LV and result in
artifactual pseudodyskinesis of the posterior wall
(Fig. 5; Online Video 3).
Assessment for underlying CAD is often accom-
plished with dobutamine stress echocardiography
(DSE), which is presumed to mimic the hemody-
namic stress of LT (15). Initial studies evaluating
DSE in the LT candidate were promising (Table 3).
Donovan et al. (25) compared DSE to coronary
angiography in a limited subset of 18 patients and
found a sensitivity of 75% and specificity of 57%.
Subsequently, Plotkin et al. (26) evaluated a higher
risk group of patients with ESLD and found a
sensitivity of 100% and specificity of 100% for
significant CAD (coronary stenosis 70%). More
recent studies have cast a doubt on the utility of
DSE as a screening tool for CAD in this patient
population (Table 3). In evaluating 64 patients for
obstructive CAD (stenosis 50%) with DSE,
Harinstein et al. (27) found a sensitivity of 17% and
specificity of 88%. Similarly, Patel et al. (19) eval-
uated 205 patients for severe CAD (stenosis70%)
with DSE and found a sensitivity of 60% and
specificity of 69% (Fig. 6; Online Video 4).
The prognostic value of DSE in predicting in-
traoperative cardiac events has also been examined.
Umphrey et al. (28) found that maximum heart rate
achieved during DSE may be a predictor of adverse
cardiovascular events in the perioperative setting.
However, both Williams et al. (29) and Findlay et
al. (30) demonstrated poor correlation between a
positive DSE and significant intraoperative cardiac
events (Table 4). It has been suggested that the
conflicting diagnostic performance of DSE may beFigure 3. Flow Related
End Stage Liver Disea
(A) Right ventricular in
vena cava consistent w
peak gradient of 3.09
gradient of 38 mm Hg
(See Online Video 2.)due to the differing study definitions of CAD,
1.
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109retrospective analysis, lack of identification of mul-
tivessel disease and a high rate of nondiagnostic
studies related to inadequate heart rate response
(15). Finally the low accuracy for predicting events
may be related to an etiology for events not depen-
dent on obstructive CAD.
SPECT has been evaluated as a screening tool
for CAD in LT candidates, likewise with variable
results (Table 3). Davidson et al. (31) evaluated
stress myocardial perfusion imaging in LT candi-
dates without known CAD and found a sensitivity
of 37% and specificity of 63% when compared to
coronary angiography. Defining only reversible per-
fusion abnormalities as indicative of a positive
SPECT study, Aydinalp et al. (32) revealed a
sensitivity of 100% and specificity of 61% when
compared to coronary angiography. In this study,
however, fixed perfusion defects were classified as
normal or minimal CAD (32). Zoghbi et al. (33)
examined the usefulness of SPECT to predict
cardiovascular complications and found that a nor-
mal SPECT study had a 99% negative predictive
value for perioperative cardiac events, although this
was in a low-risk cohort of patients. A more recent
study found a low proportion of positive stress
myocardial perfusion imaging results (7%) in a
population of 772 consecutive adult LT candi-
dates—a finding that is incongruous with the re-
ported prevalence of CAD in this patient popula-
tion (34). This study also reported a substantially
lower rate of cardiovascular complications which
were not well predicted by pre-transplant imaging.
Several newer modalities are being evaluated for
the noninvasive assessment of CAD in LT candi-
dates. Coronary artery calcification scoring has been
well validated as an independent risk factor for
CAD in the general population (35), but currently,
there are only limited data utilizing this modality in
LT candidates (36,37). Cardiac CTA is emerging
as a potential noninvasive alternative for pre-
operative evaluation. Keeling et al. (38) reported a
prevalence of CAD of 90.8% in LT candidates
using CTA, although without confirmation with
coronary angiography. Cassagneau et al. (39) re-
cently compared the prognostic value of CTA with
DSE and found a comparably high negative pre-
dictive value for major cardiac adverse events with
CTA and DSE. Although CTA appears promising,
several limitations exist for this patient population
including the need for tight heart-rate control,
breath-holding during the test, and the potential for
contrast-induced renal impairment (15). Keeling et
al. (38) revealed that over a quarter of patients hadpoor image quality due to these limitations. CMR is
a developing technology that would allow for a
complete noninvasive assessment of the LT candi-
date but has not been studied in this patient
population and shares many of the limitations as
CTA (15).
Coronary angiography remains the gold standard
for the diagnosis of CAD. It has been suggested
that coronary angiography should be used in all LT
candidates with known CAD due to the high rates
of morbidity and mortality in this subset of LT
candidates (1,16). However, coronary angiography
should not be used as the initial screening test as it
is invasive, carries increased risk in ESLD patients
who may be coagulopathic, and can lead to
Figure 4. Doppler Evidence of Diastolic Dysfunction
Transmitral Doppler inﬂow and annular velocity in a patient with ES
abnormal mitral inﬂow and annular tissue velocities consistent with
tion. This patient also appears in Figure 1. Abbreviation as in FigureLD documenting
diastolic dysfunc-contrast-induced renal failure (38).
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110Based on existing evidence, the AASLD, the
American Heart Association (AHA), and the
American College of Cardiology Foundation
(ACCF) have established guidelines for pre-
operative CAD assessment in LT candidates
(24,40). These guidelines agree that LT candidates
should undergo an evaluation for CAD based on
the presence of risk factors. Depending on the
committee, these risk factors include a history of
smoking, diabetes mellitus, hypertension, hyperlip-
idemia, clinical or family history of heart disease,
LVH, or age 50 years versus 60 years (24,40).
he AASLD also states that DSE appears to be an
ffective screening test in this setting with coro-
ary angiography recommended for all positive
esults. It should be emphasized that the recom-
endation for use of DSE is a consensus opinion
nd not one based on robust comparative trials.
n clinical practice, multiple modalities have
ound reasonable success, and in the absence of
ore robust data, the choice of provocative test-
ng in LT candidates is probably best determined
y local expertise.
Other Cardiovascular Considerations
LVOTO and hypertrophic cardiomyopathy. The base-
line hyperdynamic systolic function and low periph-
eral vascular resistance in the setting of LVH
predisposes LT candidates to hypotension or to
development of LVOTO during DSE or in the
setting of decreased intraoperative preload. Maraj et
al. (41) found that 43% of patients had inducible
LVOTO on pre-operative DSE, defined as an
outflow tract gradient of 36 mm Hg (Fig. 7;
Online Video 5). These patients had a significantly
increased risk of intraoperative hypotension but no
significant increase in post-operative mortality (41).
In rare cases, the LT candidate may have LVOTO
secondary to concomitant hypertrophic cardiomy-
opathy (42,43). The finding of LVOTO necessi-
Table 2. Prevalence of CAD in LT Candidates
Author (Year) (Ref. #)
No. of
Patients
Patient Age,
yrs
Prevalence of
CAD, %
Carey et al. (1995) (17) 37 50–71 27*
Tiukinhoy-Laing et al.
(2006) (18)
161 57 7 26†
Patel et al. (2011) (19) 420 56 8 18*
*Deﬁned as coronary stenosis 30% on coronary angiography. †Deﬁned as
coronary stenosis 50% on coronary angiography.
CAD  coronary artery disease; LT  liver transplant.tates careful intraoperative monitoring withavoidance of hypovolemia, tachycardia, and ino-
tropic agents. Furthermore, in the setting of
LVOTO and diastolic dysfunction, invasive mea-
surement of cardiac filling pressures may provide
erroneous information for assessment of ventric-
ular volume, especially in the post-reperfusion
period (42). Intraoperative TEE can play a crit-
ical role for continuous monitoring of ventricular
volumes and dynamic LVOTO, guiding the use
of volume resuscitation and vasopressor therapy
(42,43).
Valvular heart disease. Limited data exist on the
incidence and relevance of valve dysfunction in LT
candidates. In a retrospective study, Alper et al. (44)
reported that 27.5% of LT candidates had evidence
of either mitral regurgitation, tricuspid regurgita-
tion, or both. Furthermore, systemic vascular resis-
tance was significantly decreased in patients with
mitral regurgitation, and cardiac output was signif-
icantly increased in patients with isolated mitral
regurgitation or mitral and tricuspid regurgitation
as compared to controls (44). Although these he-
modynamic changes did not affect overall mortality,
more patients with either isolated mitral regurgita-
tion or mitral and tricuspid regurgitation experi-
enced intraoperative hypotension requiring vaso-
pressor therapy (44).
Aortic stenosis results in LV pressure overload
with compensatory ventricular hypertrophy and de-
creased LV compliance. These hemodynamics are
exaggerated during LT due to profound fluid shifts
resulting in a sudden decrease in preload during
Figure 5. Parasternal Short-Axis View Recording in a
Patient With ESLD
Note the posterior compression of the LV by the ascites (long
arrow) resulting in a D-shaped LV with ﬂattening of the posterior
wall in diastole (arrowheads). In the real-time clip, note the restitu-
tion of circular LV geometry in systole resulting in posterior wall pseu-
dodyskinesis. Abbreviations as in Figure 1. (See Online Video 3.)
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111liver resection and impaired myocardial contractility
during the post-reperfusion syndrome. The pres-
ence of severe aortic stenosis in the LT candidate
requires a collaborative approach, and only case
reports have documented successful LT in these
patients (45,46). Although TTE is an important
noninvasive method for evaluating the severity of
aortic stenosis, it requires careful interpretation in
Figure 6. DSE Performed 6 Months Following Liver Transplanta
Pre-operative dobutamine stress echocardiography (DSE) had revea
coronary artery disease (CAD). The patient subsequently developed
ﬁndings consistent with left anterior descending coronary artery isc
Table 3. Accuracy of DSE and SPECT Imaging in the Detection o
Type of Stress Testing/Author (Year) (Ref. #) No. of Patien
DSE
Donovan et al. (1996)* (25) 18
Plotkin et al. (1998)† (26) 40
Harinstein et al. (2008)* (27) 64
Harinstein et al. (2008)† (27) 64
Patel et al. (2011)‡ (19) 205
SPECT imaging
Davidson et al. (2002)† (31) 83
Aydinalp et al. (2009)‡§ (32) 93
*CAD deﬁned as coronary stenosis 50% in 1 or more arteries. †CAD deﬁned a
70% in 1 or more arteries. §SPECT imaging considered non-ischemic if norm
DSE  dobutamine stress echocardiography; NPV  negative predictive v
tomography; other abbreviations as in Table 2.ESLD. As a result of high transvalvular flows,
reliance on aortic valve gradients alone may result
in overestimation of the degree of obstruction
and calculation of aortic valve area is thus essen-
tial (45). Although additional echocardiographic
findings such as LVH can support the diagnosis
of advanced aortic stenosis, it can be present in
cirrhotic cardiomyopathy alone (45). When echo-
a normal hyperdynamic response and suggested the absence of
st discomfort following transplant and a repeat study revealed
ia with dyskinesis of the distal septum (arrow) at peak dobut-
AD in LT Candidates
Sensitivity, % Speciﬁcity, % PPV, % NPV %
75.0 57.1 33.3 88.9
100.0 100.0 100.0 100.0
16.7 87.5 44.4 63.6
12.5 85.4 22.2 74.5
60 68.9 21.1 92.5
36.8 62.5 22.6 76.9
100.0 60.9 15.0 100.0
onary stenosis 70% in 1 or more arteries. ‡CAD deﬁned as coronary stenosis
rfusion or ﬁxed defects.
PPV  positive predictive value; SPECT  single photon emission computedtion
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112cardiographic data are in question, cardiac cath-
eterization should be performed to assess the
hemodynamic severity.
Hepatopulmonary syndrome. Hepatopulmonary
syndrome (HPS) is characterized by the presence of
abnormal intrapulmonary vascular dilatations re-
ng a Normal Hyperdynamic Response and Evidence of Dynamic
tion
ote the systolic anterior motion of the mitral valve (arrow) and
ic LV outﬂow track gradient of 86.6 mm Hg. Abbreviations as in
nline Video 5.)
Table 4. Prognostic Value of DSE for Signiﬁcant Intraoperative
Author, Year, (Ref. #) Number of Patients
Williams et al. (2000)* (29) 71
Findlay et al. (2005)† (30) 73
*Signiﬁcant intraoperative cardiac event deﬁned as arrhythmia, cardiac arrest, or d
T measured after transplantation.
Abbreviations as in Table 3.sulting in a compromise of pulmonary gas exchange
in patients with advanced liver disease (47,48). The
prevalence of HPS is approximately 20% in LT
candidates but clinically significant HPS with arte-
rial hypoxemia is identified in 5% (47). The
pathogenesis of HPS is linked to an imbalance
between vasoconstrictors and vasodilators leading to
pulmonary vascular dilatation at the pre-capillary
and capillary level (47,49). This results in intrapul-
monary shunting, ventilation–perfusion mismatch,
and hypoxemia with clinical presentation of pro-
gressive hypoxia, dyspnea, and cyanosis (48,50). LT
may be curative in some patients with mild to
moderate HPS (48). The diagnosis of HPS is
established based on 3 criteria: evidence of chronic
liver disease, hypoxemia at rest, and evidence of
intrapulmonary vascular shunting (49,50). The gold
standard for demonstration of intrapulmonary
shunting is saline contrast echocardiography
(49,50) (Fig. 8; Online Video 6). Appearance of
agitated saline on the left side of the heart in HPS
is dependent on the time it takes for transpulmo-
nary blood flow and can occur within 4 to 5 beats in
patients with increased cardiac output or be delayed
by 8 to 10 beats if the cardiac output is depressed.
With intrapulmonary shunting, contrast will be
visualized in the pulmonary veins and may continue
to appear in the left side of the heart even after there
has been clearance of saline from the right side of
the heart. This is in contrast to intracardiac shunts
where appearance of contrast in the left heart is
dependent on the pressure gradient between the RA
and LA and is thus respiratory dependent and
phasic in appearance (Table 5) (49,50). Detection
of intrapulmonary shunts may also be improved by
performing contrast-enhanced echocardiography in
the standing position (51). Alternatively, techne-
tium-99m–labeled macroaggregated albumin per-
fusion scanning can be utilized to diagnose HPS.
Under normal conditions, the majority of labeled
albumin is trapped within the pulmonary circula-
tion. In the presence of intrapulmonary shunting,
the albumin is not completely trapped in the lungs
iac Events
ensitivity Speciﬁcity PPV NPV
0.0% 96.2% 0.0% 86.4%
20.0% 90.5% 25.0% 87.7%
. †signiﬁcant intraoperative cardiac event deﬁned as elevation of cardiac troponinFigure 7. DSE Reveali
Outﬂow Tract Obstruc
At peak dobutamine, n
the late peaking dynam
Figures 1 and 6. (See OCard
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113quantified by its appearance in other organs, includ-
ing the brain, liver, and spleen (49,50). Obviously,
atrial septal defect needs to be excluded as it will
also result in isotope appearance in the liver. Pul-
monary angiography is not commonly used for the
diagnosis of HPS but allows for the direct visual-
ization of intrapulmonary vascular malformations
(49,50).
Figure 8. Saline Contrast Echocardiography Performed in a Pati
Pulmonary AVM
The upper left panel is immediately after appearance of contrast in
and reveals nearly continuous ﬂow into the LA and LV. The lower l
equal contrast in both the right and left ventricles and the lower ri
continued appearance of contrast into the LV when contrast is dim
other abbreviations as in Figure 1. (See Online Video 6.)
Table 5. Characteristics of Intrapulmonary Shunts and
Intra-Cardiac Shunts on Saline Contrast Echocardiography
Shunt Type Contrast Appearance on Left Side of Heart
Intrapulmonary Dependent on time necessary for
transpulmonary blood ﬂow;
contrast visualized in pulmonary veins;
continuous appearance;
can appear after clearance of contrast
from right side of heart
Intracardiac Dependent on interatrial pressure gradient;
occurs when RAP exceeds LAP;
respiratory dependent;
phasic appearance
LA  left atrium; LAP  left atrial pressure; RA  right atrium; RAP  rightyatrial pressure.Portopulmonary hypertension. Portopulmonary hy-
pertension (PPH) is a form of pulmonary arterial
hypertension associated with portal hypertension
with or without accompanying cirrhosis (52,53).
PPH is hypothesized to occur: 1) as a result of
increased vascular wall shear stress resulting in
endothelial dysfunction; and 2) due to the porto-
systemic shunting of vasoactive substances from the
splanchnic circulation to the pulmonary circulation,
leading to progressive pulmonary vascular vasocon-
striction and remodeling (52,53). Hemodynami-
cally, the diagnostic criteria for PPH includes a mean
pulmonary artery pressure (mPAP)25 mm Hg at rest,
mean pulmonary capillary wedge pressure15 mm Hg,
and pulmonary vascular resistance 240 dynes/s/
cm–5 (50,53). Risk factors for the development of
PH include female sex and autoimmune hepatitis,
hile ESLD secondary to hepatitis C is associated
ith a decreased risk of PPH (54). Clinically,
atients with PPH are asymptomatic for months to
With ESLD Revealing Marked Right-to-Left Shunt Through
ht heart. The upper right panel is 5 beats following appearance
anel is approximately 10 s after injection of contrast and reveals
panel is recorded 15 s following injection of contrast and reveals
ing in the right ventricle. AVM  arteriovenous malformation;ent
rig
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114syncope, and chest pain later in the disease course
(49,53). Small studies have demonstrated that
pre-operative mPAP 35 mm Hg is associated
with no significant increased mortality, pre-
operative mPAP between 35 and 50 mm Hg is
associated with a 50% mortality, and pre-
operative mPAP 50 mm Hg is associated with
ortality approaching 100% after LT (55). Many
ransplant centers consider PPH with a pre-
perative mPAP 50 mm Hg a contraindication
o LT due to the increased risk, uncontrollable
ntraoperative bleeding, and reduced transplant
rgan perfusion post-transplantation (56).
The AASLD and the AHA/ACCF recommend
creening for elevated pulmonary pressures in all
T candidates with Doppler echocardiography
24,40) (Fig. 9; Online Video 7). Utilizing the peak
ricuspid regurgitant velocity (TRV), the estimated
A pressure (RAP), and the modified Bernoulli
ld Man With PPH Related to ESLD
er view reveals a markedly dilated right ventricle and right
tricuspid regurgitation. B: Continuous wave Doppler documents a
etween the right ventricle and the right atrium consistent with
ertension. PPH  portopulmonary hypertension; other abbrevia-
e Online Video 7.)quation, the RV systolic pressure (RVSP) can be
alculated as: 4(TRV)2  RAP (49,52). In the
absence of pulmonic stenosis, the pulmonary sys-
tolic pressure is equivalent to the RVSP. In LT
candidates undergoing screening for PPH, TTE
has a sensitivity of 97% and a specificity of 77% for
diagnosing elevated pulmonary pressures (57).
These pressures must be interpreted carefully as up
to 20% of LT candidates show moderately in-
creased pulmonary pressures attributable to the
hyperdynamic state of cirrhotic cardiomyopathy,
volume overload, or LV dysfunction (53,58), while
only 5% to 10% of LT candidates have elevated
pulmonary pressures due to PPH (59). This distinc-
tion is critical as patients with elevated pulmonary
pressures for etiologies other than PPH do not have
an increased rate of adverse events with LT (58).
The AASLD and AHA/ACCF recommend right
heart catheterization with calculation of pulmonary
vascular resistance for confirming the diagnosis of
PPH when an RVSP of 45 to 60 mm Hg is found
(24,40). Recent case series and retrospective analy-
ses have shown that successful LT can be facilitated
in patients after reduction in pulmonary pressures
with pharmacotherapy (55,60).
Pericardial effusions. LT candidates characteristi-
ally have fluid retention, manifest as a combination
f peripheral edema, ascites, pleural effusions, and
ericardial effusion (55,60). Pericardial effusions are
eported in up to 63% of patients with ESLD, but
re typically small in size and hemodynamically well
olerated (61). While the evaluation of a pericardial
ffusion should include determination of the size,
ircumferential extent, and presence or absence of
emodynamic compromise, the development of
ardiac tamponade in the LT candidate is rare and
as been reported only in isolated case reports
61,62).
Patent foramen ovale. Patent foramen ovale (PFO)
is present in a quarter of the general population, and
typically portends a benign course (63). Contrast-
enhanced echocardiography or color Doppler im-
aging is recommended for the diagnosis of PFO. In
the setting of LT, spontaneous echogenic contrast
material representing air and/or microthrombi is
seen in the right heart of all patients at the time of
donor liver reperfusion (64). Hypothetically,
changes in intracardiac pressure during the periop-
erative period can result in paradoxical emboli.
Some studies have reported an increased risk of
embolic events in patients with a PFO during LTFigure 9. A 57-Year-O
(A) The apical 4-chamb
atrium and moderate
106-mm Hg gradient b
severe pulmonary hyp
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115no significant difference in outcomes for patients
with a PFO (65).
Assessing Risk of Specific Procedures
Risk of transjugular intrahepatic portosystemic shunt
procedure. Insertion of a transjugular intrahepatic
ortosystemic shunt (TIPS) is standard treatment
or refractory ascites and uncontrolled variceal
leeding (7,9,66,67). Placement of a TIPS results in
n abrupt increase in cardiac preload due to a shift
f portal venous blood into the systemic circulation,
eading to an additional increase in cardiac output,
ncreased LV and RV end-diastolic volumes, and
urther decrease in systemic vascular resistance (4).
hese acute hemodynamic effects in the setting of
irrhotic cardiomyopathy can result in high-output
ongestive heart failure, cardiac arrhythmias, and
yocardial ischemia (4). In a study comparing
utcomes of TIPS to repeated large-volume para-
entesis, Ginès et al. (68) found that 12% of the
IPS group developed heart failure as compared
o none in the paracentesis group. Similarly,
chwartz et al. (69) found that 13% of patients
eveloped heart failure after TIPS placement.
ore recently, Cazzaniga et al. (67) reported that
he presence of diastolic dysfunction (defined as
/A ratio 1) 4 weeks post-TIPS was the only
independent predictor of overall survival follow-
ing the procedure. Rabie et al. (66) revealed that
the presence of diastolic dysfunction in the pre-
TIPS period predisposed patients to both cardiac
and noncardiac death post-procedure. Given
these findings, it has been suggested that after
TIPS insertion, patients with evidence of dia-
stolic dysfunction should be preferentially con-
Figure 10. Serial Echocardiograms in a Patient With Acute Decom
End systolic apical 4-chamber view recorded 24 h after an otherwis
severe systolic dysfunction and clinical congestive heart failure (left
tion and there was full recovery of function 3 months later (right psidered for LT as compared to patients with
normal diastolic function (67).
Acute effects of liver transplantation. LT imposes
mmediate stress on the heart. Intraoperatively,
here is impaired myocardial contractility with an
brupt increase in peripheral vascular resistance and
sudden decrease in preload which can be further
xacerbated by hemorrhage, third space fluid losses,
nd inadequate volume resuscitation, resulting in
educed cardiac output (4,8,9). Conversely aggres-
ive fluid repletion or blood transfusion can result in
olume overload and the development of pulmonary
dema due to occult cardiac disease. Pulmonary
dema occurs in 12% to 56% of LT candidates in
he perioperative period (9,25). Metabolic derange-
ents related to post-reperfusion syndrome can
urther impair cardiac contractility. The stress of
T can thus unmask the latent systolic dysfunc-
ion of cirrhotic cardiomyopathy, leading to overt
eart failure (Fig. 10; Online Video 8) with heart
ailure and other cardiac complications account-
ng for 7% to 21% of mortality following LT
8,9). Unfortunately, there are no reliable diag-
ostic criteria to identify LT candidates with
irrhotic cardiomyopathy at risk of developing
ardiac complications in the perioperative period.
im et al. (10) evaluated the use of DSE for
dentifying patients with cirrhotic cardiomyopa-
hy and found a blunted DSE response (defined
s 10% reduction in LV end-diastolic volume,
20% decrease in end-systolic volume, and
10% increase in LV ejection fraction) in 25% of
T candidates. However, the prognostic value of
blunted DSE in predicting perioperative com-
lications is unknown (4).
sation Following Liver Transplantation
ccessful liver transplant (LT) in a patient who developed acute
el). Pre-operative testing had revealed normal LV systolic func-
l). Abbreviation as in Figure 1. (See Online Video 8.)pen
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116Heart Diseases Causing Liver Disease
Occasionally, pre-operative evaluation of the LT
candidate reveals cardiac disease as the etiology of
ESLD. This syndrome termed cardiac cirrhosis is
characterized by chronic right heart failure leading
to elevated systemic venous pressures, passive he-
patic venous congestion and subsequent sinusoidal
collagen deposition and eventual cirrhosis (4,49).
Cardiovascular diseases that may result in cardiac
cirrhosis include dilated cardiomyopathy with sec-
ondary pulmonary hypertension, restrictive cardio-
myopathy, constrictive pericarditis (Fig. 11; Online
Video 9), primary pulmonary hypertension, or mi-
tral stenosis with secondary pulmonary hyperten-
sion (4,49). The clinician should suspect cardiac
cirrhosis when the triad of right heart failure,
hepatomegaly, and ascites with a high protein
content and high serum ascites albumin gradient
is present (4,49). Ultimately, the combined use of
liver vein catheterization with liver tissue sam-
pling and right heart catheterization can help to
discriminate between portal hypertension and
right-sided heart failure (4). As the treatment of
cardiac cirrhosis is based on treatment of the
underlying cardiac disorder, there is no role for
LT in this syndrome (49).
Recommendations
Cardiovascular complications account for consider-
able mortality and morbidity associated with LT.
The AASLD and the AHA recommend TTE for
all LT candidates to evaluate cardiac chamber sizes,
systolic and diastolic function, valvular function,
and pulmonary artery pressure and to exclude the
presence of intracardiac shunts, significant LVOTO, or
pericardial effusion (24,40). Additional noninvasive
unctional assessment for CAD is recommended for
T candidates based on the presence of risk factors
24,40). The cardiac imaging modality of choice for
oninvasive screening of CAD remains unclear. As
SE appears to be an effective screening test and
an provide a comprehensive cardiac assessment, it
s currently recommended by the AASLD (24).
able 6 provides a summary of these recommenda-
ions based on the body of evidence reviewed. The role
f cardiac imaging in the evaluation of the LT
andidate continues to be in evolution. Further studies
re necessary to develop an evidence-based approach
o the diagnosis of underlying cardiac pathology (es-
ecially CAD) and identify the subset of patients at
ncreased risk of cardiovascular complications.Reprint requests and correspondence: Dr. William F.
rmstrong, University of Michigan Medical Center,
epartment of Internal Medicine, Division of Cardiol-
gy, Cardiovascular Center Floor 2 Room 2161, 1500
ast Medical Center Drive SPC 5853, Ann Arbor,
ichigan 48109-5853. E-mail: wfa@umich.edu.
Figure 11. Two-Dimensional Echocardiogram Recorded in a
56-Year-Old Man With ESLD Related to “Cryptogenic
Cirrhosis”
Echocardiography at the time of transplant evaluation revealed
classic ﬁndings of pericardial constriction. In the apical 4-cham-
ber view (A), note the rightward shift of the ventricular septum
(arrows) in this inspiratory still frame. In the real-time image,
the respiratory variation of septal position is better appreciated.
Transmitral (B) and transtricuspid (C) Doppler conﬁrm exagger-
ated respiratory variation consistent with constriction. Abbrevia-
tion as in Figure 1. (See Online Video 9.)
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117Table 6. Pre-Operative Cardiovascular Assessment
Cardiovascular Finding Screening Recommendations Limitations/Considerations
Coronary artery disease DSE evaluation for all patients 50 yrs old, chronic
smokers, diabetes, family or clinical history of heart
disease
Low sensitivity and low NPV in some studies;
frequent inability to reach target heart rate (study
nondiagnostic);
numerous proposed diagnostic algorithms;
coronary angiography recommended for
conﬁrmation of positive studies
Cirrhotic cardiomyopathy Echocardiography to assess systolic/diastolic function, LVH,
cardiac chamber sizes
No diagnostic criteria available
LVOTO/HCM Echocardiography Diagnosis of HCM can be difﬁcult in setting of
underlying cirrhotic cardiomyopathy, LVOTO;
intraoperative TEE monitoring to assess ventricular
volumes and dynamic LVOTO
Valvular heart disease Echocardiography Hyperdynamic circulatory state with high transvalvular
ﬂow can overestimate degree of valve stenosis
Portopulmonary hypertension Doppler echocardiography Inability to distinguish between pulmonary arterial
hypertension and pulmonary venous hypertension;
right heart catheterization recommended for
diagnosis conﬁrmation
Hepatopulmonary syndrome Contrast echocardiography Must be differentiated from atrial septal defect and
patent foramen ovale
Pericardial effusion Echocardiography Assessment for cardiac tamponade; frequent
reaccumulation due to underlying ESLD
Patent foramen ovale Contrast echocardiography Signiﬁcance of diagnosis unclear; intraoperative TEE
monitoring for prevention of venous air emboli
HCM  hypertrophic cardiomyopathy; LVH  left-ventricular hypertrophy; LVOTO  left-ventricular outﬂow tract obstruction; TEE  transesophageal echocardiography.1
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